Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Acquires 24,000 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young acquired 24,000 shares of the stock in a transaction on Monday, January 27th. The shares were bought at an average price of $5.40 per share, for a total transaction of $129,600.00. Following the purchase, the chief financial officer now owns 24,000 shares in the company, valued at approximately $129,600. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

TriSalus Life Sciences Trading Down 0.8 %

TLSI traded down $0.04 during trading on Wednesday, reaching $4.93. 16,469 shares of the company’s stock were exchanged, compared to its average volume of 23,643. The firm has a fifty day moving average price of $4.55 and a two-hundred day moving average price of $4.75. TriSalus Life Sciences, Inc. has a one year low of $3.50 and a one year high of $10.42. The stock has a market capitalization of $150.32 million, a PE ratio of -1.98 and a beta of 0.51.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TLSI. Northland Securities started coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target for the company. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Mkm restated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target on the stock. Finally, Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $11.79.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors have recently modified their holdings of the company. Walleye Capital LLC acquired a new stake in TriSalus Life Sciences in the third quarter worth $66,000. Virtu Financial LLC purchased a new position in TriSalus Life Sciences during the 3rd quarter worth $92,000. Vestcor Inc purchased a new stake in TriSalus Life Sciences in the 3rd quarter valued at about $108,000. MSD Partners L.P. purchased a new position in TriSalus Life Sciences in the third quarter worth $184,000. Finally, Geode Capital Management LLC increased its holdings in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares during the last quarter. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.